Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies

Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies

Thrombotic microangiopathy (TMA) is most of the time caused by thrombotic thrombocytopenic purpura or hemolytic uremic syndrome. A 60-year-old female was diagnosed in 2014 with mammary breast adenocarcinoma treated by several-line therapy: mastectomy, docetaxel, cyclophosphamide, radiotherapy, doxor...

Full description

Bibliographic Details
Main Authors: Quentin Perrier, Johan Noble, Steven Grangé, Pierrick Bedouch, Rachel Tetaz, Lionel Rostaing
Format: Article
Language:English
Published: Karger Publishers 2021-04-01
Series:Case Reports in Oncology
Subjects:
thrombotic microangiopathy
breast cancer
eculizumab
atypical hemolytic uremic syndrome
complement
palbociclib
metastases
Online Access:https://www.karger.com/Article/FullText/514982

Internet

https://www.karger.com/Article/FullText/514982

Similar Items